These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 24840624

  • 1. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
    Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA.
    J Antimicrob Chemother; 2014 Sep; 69(9):2547-55. PubMed ID: 24840624
    [Abstract] [Full Text] [Related]

  • 2. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [Abstract] [Full Text] [Related]

  • 3. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC.
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [Abstract] [Full Text] [Related]

  • 4. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY, Liao CH, Wang JL, Chiang WC, Lai MS, Chie WC, Chang SC, Hsueh PR.
    J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
    [Abstract] [Full Text] [Related]

  • 5. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y, Song KH, Cho Je, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD.
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [Abstract] [Full Text] [Related]

  • 6. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
    Chang HJ, Hsu PC, Yang CC, Siu LK, Kuo AJ, Chia JH, Wu TL, Huang CT, Lee MH.
    J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
    Kan LP, Lin JC, Chiu SK, Yeh YC, Lin TY, Yang YS, Wang YC, Wang NC, Yeh KM, Chang FY.
    J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
    [Abstract] [Full Text] [Related]

  • 9. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.
    Rojas L, Bunsow E, Muñoz P, Cercenado E, Rodríguez-Créixems M, Bouza E.
    J Antimicrob Chemother; 2012 Jul; 67(7):1760-8. PubMed ID: 22556382
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Ghosh N, Chavada R, Maley M, van Hal SJ.
    Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
    [Abstract] [Full Text] [Related]

  • 12. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome.
    Kim T, Kim ES, Park SY, Sung H, Kim MN, Kim SH, Lee SO, Choi SH, Jeong JY, Woo JH, Chong YP, Kim YS.
    Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1473-1481. PubMed ID: 28337607
    [Abstract] [Full Text] [Related]

  • 13. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
    Hos NJ, Jazmati N, Stefanik D, Hellmich M, AlSael H, Kern WV, Rieg S, Wisplinghoff H, Seifert H, Kaasch AJ.
    J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
    Joo J, Yamaki J, Lou M, Hshieh S, Chu T, Shriner KA, Wong-Beringer A.
    Clin Ther; 2013 Jul; 35(7):995-1004. PubMed ID: 23829982
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA.
    Clin Infect Dis; 2014 Sep 01; 59(5):666-75. PubMed ID: 24867791
    [Abstract] [Full Text] [Related]

  • 19. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H, Maeda M, Shirakura T, Takuma T, Ugajin K, Fukuchi K, Ishino K, Niki Y.
    Int J Antimicrob Agents; 2015 Nov 01; 46(5):532-7. PubMed ID: 26364848
    [Abstract] [Full Text] [Related]

  • 20. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R, Davis SL, Levine DP, Rybak MJ.
    Clin Infect Dis; 2011 Apr 15; 52(8):975-81. PubMed ID: 21460309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.